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Introduction
Pancreatic cancer is one of the most aggressive gastrointestinal
malignancies with mortality rates closely following the inci-
dence rates [1]. The incidence is increasing and the prognosis
is grim especially because of late diagnosis and metastatic po-
tential. While surgical treatment is currently the only potential
curative intervention, 80–85% of the pancreatic cancer cases
are unfortunately detected in advanced unresectable stages of
Endoscopic ultrasound guided needle-based confocal laser endo-
microscopy in solid pancreatic masses – a prospective validation
study
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ABSTRACT
Background and study aims Endoscopic ultrasound fine-
needle aspiration (EUS-FNA) is a keystone in diagnosing and
staging of pancreatic masses. Recently, a microfiber that
can pass through a 19-gauge needle has been introduced
for confocal laser endomicroscopy (nCLE). The aims of this
study were to evaluate the diagnostic value and the repro-
ducibility of nCLE criteria for solid malignant lesions.
Patients and methods This prospective dual-center study
included patients with pancreatic masses suspicious of ma-
lignancy referred for EUS-FNA. Endomicroscopic imaging
was performed under EUS-guidance until organ-specific
structures were obtained. Afterwards, standard cytology
was obtained and patients were followed for up to 12
months. All nCLE parameters included in former studies
were correlated with the final diagnosis (dark lobular struc-
tures/normal acinar cells, dark cell aggregates > 40µm, dila-
ted irregular vessels with fluorescein leakage, fine white fi-
brous bands, small black cell movements, pseudoglandular
structures). Finally, three CLE novices and three CLE experts
assessed the unedited movies from all patients.
Results Twenty-eight patients were enrolled in the study.
A final diagnosis was obtained in 24 patients (86%). One pa-
tient (3%) died before a diagnosis was obtained, while 3
were lost to follow-up (11%). In 18/24 patients (74%) the
diagnosis was malignant. The mean sensitivity, specificity,
and accuracy for the nCLE parameters ranged from 19–
93%, 0–56%, 26–69%, respectively. The inter-observer val-
ues ranged from κ=0.20–0.41 for novices and κ=–0.02–
0.38 for experts.
Conclusions The diagnostic value of nCLE in solid pancre-
atic masses is questionable and the inter-observer agree-
ment for both novices and CLE experts appears limited.
Original article
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the disease [2]. Furthermore, in spite of advances in the diagno-
sis and management of pancreatic cancer, less than 5% of pa-
tients are alive at five years [3].
Endoscopic ultrasound (EUS) represents a highly valuable
tool in the management of pancreatic cancer patients. As a
minimal invasive technique that enables high-resolution ima-
ging of the pancreatic parenchyma and surrounding structures,
it is considered the most sensitive method for the detection of
clinically suspected pancreatic tumors, with a negative predic-
tive value close to 100% [4]. Its diagnostic sensitivity was
shown by previous studies to be superior compared to other
imaging methods, especially in the case of small tumors [5, 6].
Additionally, EUS enables guided fine needle aspiration (EUS-
FNA), which is currently recommended as the first-line proce-
dure whenever pathological diagnosis is required [7]. However,
EUS-FNA as a sampling technique has its drawbacks, mainly re-
presented by the relatively low negative predictive value in di-
agnosing pancreatic cancer. It thus cannot reliably rule out a di-
agnosis of malignancy in a patient with a focal mass and a neg-
ative EUS-FNA and therefore patients with a high clinical suspi-
cion of malignancy usually need repeated FNA [8].
Confocal laser endomicroscopy (CLE) has emerged as a novel
technique that enables in vivo microscopic imaging during on-
going endoscopy. Endomicroscopy can be performed either
with dedicated endoscopes (eCLE) or with probe-based sys-
tems (pCLE) [9]. The principle of the method is based on a laser
beam of defined wavelength being focused towards the targe-
ted tissue, with the recaptured signal displayed as ‘optical biop-
sies’ in the horizontal plane. CLE is a contrast-based method;
the most widely used agent being intravenously administered
fluorescein, although other agents are in preclinical stages
[10]. The potential role of CLE has been explored in both the
upper and lower gastrointestinal tract, showing good accuracy
for predicting the final histopathological diagnosis based on
immediate evaluation of tissue, vascular patterns, and func-
tional defects of the intestinal barrier function [11, 12]. Recent-
ly, CLE has gone beyond the luminal indications with the intro-
duction of a novel microprobe that can be passed through a 19-
gauge EUS-FNA needle [13]. Thus, under EUS guidance solid
and cystic lesions can be accessed for real-time endomicro-
scopic information with a needle-based CLE approach (nCLE)
[14]. The feasibility of the method has been tested and gained
substantial clinical use in pancreatic cystic neoplasms [15–19].
However, a limited number of cases of solid pancreatic masses
have been described with nCLE and evidence of the suggested
imaging criteria are warranted [20–22].
The aim of this study was to estimate the feasibility and safe-
ty of EUS-guided nCLE for evaluation of solid pancreatic masses
and validate the diagnostic value of nCLE criteria for malignant
lesions. Furthermore, the reproducibility of the nCLE param-
eters and the movie quality were analyzed for both nCLE novi-
ces and international experts.
Patients and methods
The present study was a prospective, dual-center, cohort study
in selected patients referred to our departments between No-
vember 2012 and July 2015 for EUS and EUS-FNA of a suspected
pancreatic mass. The study was approved by the regional ethics
committee and the Danish Data collection authorities, and was
registered at clinicaltrials.gov (NCT01734967). All patients
signed informed consent for EUS with FNA and nCLE examina-
tion. This paper includes only patients where nCLE of pancreatic
masses were performed. The probe-based endomicroscopy
system consists of a flexible catheter probe representing a bun-
dle of optical fibers linked to a micro-objective, a laser scanning
unit, and the control and acquisition software (Mauna Kea
Technology, Paris, France). Throughout our study, we used a
small diameter probe developed for usage through a 19G nee-
dle (nCLE) for EUS-guided procedures (AQ-Flex 19™, Mauna Kea,
Paris, France). This miniprobe has a diameter of 0.85mm, a field
of view of 325µm and a 3.5 µm lateral resolution for the result-
ing images.
Patients
The indication for this investigation was based on the patient’s
clinical history and previous imaging studies (abdominal US,
CT, or MRI). Furthermore, the EUS examination had to identify
a solid pancreatic mass with an indication for EUS-FNA. Patients
with known allergy to fluorescein, being pregnant or breast
feeding, or presenting with a contraindication for EUS-FNA
were excluded. For each patient personal data, EUS variables,
histological, and cytological findings were registered.
nCLE procedures
All patients with a suspicion of pancreatic masses were evaluat-
ed by EUS, nCLE, and EUS-FNA for cytopathological diagnosis.
For the EUS examination linear instruments were used (Pentax
EG 3870 UTK, Hamburg, Europe or Olympus GF-UCT180,
Tokyo, Japan) to perform complete examination of the pan-
creas. P. V., H.H., or A. S carried out the procedures, while T. C.
or J. G. K. assisted in order to optimize the nCLE image acquisi-
tion. Tumor characteristics (echogenicity, echostructure, size,
and vascular invasion) were described. The presence of regional
lymph nodes was reported with their maximal size, echogenici-
ty, shape, and margins. Identification of liver metastases was
also looked upon by careful examinations of the liver. nCLE was
performed after EUS identification of the pancreatic mass. Initi-
ally, the confocal microprobe was preloaded into a 19-gauge
EUS-FNA needle as previously described and advanced into the
lesion under real-time EUS guidance [13]. The nCLE examina-
tion followed after intravenous administration of five mL of
fluorescein 10% (Skanderborg Pharmacy, Skanderborg, Den-
mark). Acquisition time was registered and image data were
stored digitally for offline analysis. Confocal imaging was initi-
ated when the needle was positioned in the lesion and contin-
ued until organ specific images representing the examined le-
sion were obtained. If the needle was repositioned, movie se-
quencing was paused. In order to enable a final pathological di-
agnosis, EUS-FNA was performed after the nCLE procedure. Fol-
lowing nCLE imaging, the fiber was removed and EUS-FNA per-
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formed using the same needle. All adverse events were regis-
tered systematically for the first 30 days after the procedure.
Assessment of the nCLE movies
All confocal images were registered in regard to dark lobular
structures (normal acinar cells), dark aggregates > 40µm, dila-
ted irregular vessels with fluorescein leakage, fine white fibrous
bands, small black cell movements, and pseudoglandular struc-
tures [20–22]. Furthermore, in order to validate the composite
scores proposed by Giovannini and Kongkam, these were asses-
sed [20, 21]. These analyses were post hoc as no criteria had
been described at the initiation of the study. Finally, the quality
of the nCLE images was evaluated using a five-point scale rang-
ing from 1 to 5 [13]. Three experts with extensive experience in
CLE (H. B., M. B., and P. V.) and three CLE novices (B. K., C. C.,
and S.D.) carried out the assessments in a blinded manner
(post hoc). While the novices were completely naive to CLE,
the experts had all conducted and analyzed nCLE cases from
pancreatic cysts and at least 100 luminal CLE cases. However,
none were familiar with interpretation in solid masses. Prior to
the assessment, all assessors received and reviewed a training
chart including three examples of each parameter (supplemen-
tary material). In order to analyze the intra-observer variability,
the movies were re-assessed after 48 hours by C. C. and P. V.
The nCLE were unedited during all analyses.
Final diagnosis
The final diagnosis was based on EUS-FNA cytopathology and/
or histological specimens in patients referred for surgery. Fur-
thermore, these patients were followed for up to one year. Pa-
thology samples obtained from surgical resections with cura-
tive intent as well as microhistological fragments obtained by
EUS-FNA were processed by paraffin embedding with usual
staining (hematoxylin and eosin) and subsequent immunohis-
tochemistry if necessary. For patients without positive cytology
or histology, the diagnosis was based on follow-up for up to one
year. Both pancreatic adenocarcinoma and neuroendocrine tu-
mors were defined as malignant
Statistical analysis
Mean (standard deviation [SD]) or when appropriate median
(interquartile range [IQR]) are presented. Normal distribution
was tested using visual inspection and the Shapiro –Wilk test.
Confidence intervals (CI) for proportions were calculated using
an exact binomial method. For the inter- and intra-observer
study, kappa statistics and intra-class correlations were inter-
preted according to Landis and Koch (poor = 0, slight =0–0.2,
fair = 0.21–0.4, moderate =0.41–0.6, substantial = 0.61–0.8,
almost perfect = 0.81–1) [22]. Fleiss’ kappa was used for the
single parameters in the inter-observer study, while intra-class
correlations were applied for movie quality. In the intra-observ-
er study Cohen’s kappa was used. Confidence intervals for kap-
pa statistics were calculated using a nonparametric bootstrap
method. For all statistics, SPSS Statistics v. 23 (IBM, Armonk,
New York, USA) or R version 3.2.3 (R Foundation for Statistical
Computing, Vienna, Austria) was used.
Results
Patients
A total of 28 eligible patients were enrolled in the study, 12 fe-
male and 16 male patients with a mean age 65 years (SD±12).
The majority of pancreatic lesions was located in the head
(▶Table 1). Liver metastasis or suspicious peripancreatic lymph
nodes were found in 7 (25.0%) and 10 patients (36.0%), respec-
tively. EUS-FNA was inconclusive in 2 patients (7.1%), benign in
11 cases (39.3%), and malignant in 15 (53.6%) cases. The final
diagnosis was not obtained in 3 cases (10.7%) due to loss of fol-
low-up and was further missing in 1 case (3.6%) as the patients
died before a final diagnosis was obtained. In the remaining 24
patients the diagnosis was malignant in 18 cases (64.2%) and
benign in 6 cases (21.4%). Two of the patients with pancreatic
▶ Table 1 Patient characteristics.
Patients
No 28
Age/years (SD) 64.7 (11.8)
Sex/females (%) 12 (42.8)
Location of tumor
▪ Uncinate process l (%) 1 (3.6)
▪ Head 19 (67.9)
▪ Body 5 (17.9)
▪ Tail 3 (10.7)
Size of tumor (maximal diameter)
▪ <2 cm (%) 2 (7.1)
▪ 2–4 cm (%) 57.1)
▪ >4 cm (%) 10 (35.7)
FNA diagnosis
▪ Inconclusive (%) 2 (7.1)
▪ PDAC (%) 14 (50.0)
▪ NET (%) 1 (3.6)
▪ Benign (%) 11 (39.3)
Final diagnosis
▪ Not obtained (%) 4 (14.3)
▪ PDAC (%) 17 (60.7)
▪ NET (%) 1 (3.6)
▪ Chronic pancreatitis (%) 6 (21.4)
Metastasis
▪ Liver (%) 7 (25.0)
▪ Lymph nodes (%) 10 (35.7)
SD, standard deviation; FNA, fine-needle aspiration; PDAC, pancreatic ductal
adenocarcinoma; NET, neuroendocrine tumor
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adenocarcinomas had benign cytology in the FNA and were fi-
nally diagnosed by analyzing ascites and on a Tru-cut liver biop-
sy, respectively.
Procedures
No adverse advents were registered during a 30-day follow-up.
Moreover, in all patients it was clearly feasible to do nCLE inside
pathological lesions and organ specific tissue was visualized in
all procedures (▶Fig. 1a, ▶Fig. 1b, ▶Fig. 1c, ▶Fig. 1d, ▶Vid-
eo 1, ▶Video 2). The mean quality of movies was 3.3 (SD±
1.0) when assessed by experts and 3.5 (SD±1.2) for CLE novi-
ces. The mean image acquisition time was 214 seconds (SD±
76) and the median number of needle repositioning in order
to optimize nCLE imaging was 3 (IQR 3.0).
Diagnostic value
For single nCLE parameters, the mean sensitivity, specificity,
accuracy, negative predictive value, and positive predictive val-
ue are presented in ▶Table2. While the most sensitive param-
eter for malignancy was small black cell movements for the ex-
perts (93%, 95%CI: 79–98%), dark aggregates > 40µm was the
sensitive parameter for the CLE novices (70%, 95%CI: 56–82%).
When we evaluated the composite score of dark aggregates
> 40µm or dilated irregular vessels with fluorescein leakage
(Giovannini et al.), we found a sensitivity of 80% (95%CI: 62–
91%) for experts and 78% (95%CI: 67–88%) for CLE novices,
while the specificity was 5% (95%CI: 0–22%) and 24% (95%CI:
7–44%) for experts and CLE novices, respectively (▶Table 3)
[21]. With the presence of dark lobular structures/normal aci-
nar cells alone, the sensitivity and specificity of a benign diag-
nosis was 50% (95%CI: 20–75%) and 82% (95%CI: 74–89%),
respectively for experts and 50% (95%CI: 20–75%) and 89%
(95%CI: 80–95%), respectively for CLE novices. However,
when dark lobular structures/normal acinar cells was combined
with fine white fibrous bands, the sensitivity rose to 83% (95%
CI: 67–93%) and 89% (95%CI = 67%-100%) for experts and CLE
novices, respectively. Of note, the negative predictive value of
this combination was 88% (95%CI: 60–97%) for experts and
94% (95%CI: 72–100%) for CLE novices.
▶ Fig. 1 a nCLE of benign pancreatic lesion (chronic pancreatitis) displaying normal acinar cells (arrow). b Fine white fibrous bands from a be-
nign pancreatic lesion probably representing fibrotic tissue. c Dark aggregates > 40µm in a pancreatic ductal adenocarcinoma. d Dilated irreg-
ular vessels with fluorescein leakage in a patient with pancreatic ductal adenocarcinoma.
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Inter and intra-observer analysis
For experts, the inter-observer analysis for the nCLE parameters
showed poor or slight agreement for dark lobular structures/
normal acinar cells, small black cell movements, and pseudo-
glandular structures, while the agreement was fair for dark ag-
gregates > 40µm, dilated irregular vessels with fluorescein
leakage, fine white fibrous bands, and nCLE movie quality
(▶Table 4). For CLE novices, the inter-observer analysis for the
nCLE parameters showed fair agreement for dark lobular struc-
tures / normal acinar cells, dark aggregates > 40µm, dilated ir-
regular vessels with fluorescein leakage, small black cell move-
ments, pseudoglandular structures, and nCLE movie quality,
while it was moderate for fine white fibrous bands (▶Table 4).
Both for experts and CLE novices, the intra-observer variability
ranged from slight to almost perfect (▶Table4). The highest
value was found for pseudoglandular structures with κ=0.93
(95%CI: 0.63–1.00) and 0.93 (95%CI: 0.52–1.00) for experts
and CLE novices, respectively.
Discussion
In this prospective validation study we investigated the feasibil-
ity and safety of EUS-guided nCLE examination of pancreatic
masses and the diagnostic value of the single nCLE parameters
as well as the proposed nCLE criteria. We found the method fea-
sible and safe, while the diagnostic value and the reproducibil-
ity were limited.
When introducing new methods and equipment, safety is
crucial. nCLE is a non-traumatic method guided by EUS though
a standard 19-gauge needle, so apart from the known adverse
events related to FNA itself, one would not expect problems
related to the insertion of the miniprobe and the acquisition of
images. Furthermore, fluorescein as an intravenously adminis-
tered contrast agent has been used for decades with adverse
events being mild and transient [10]. In this study we did not
register any adverse events, which corresponds well with other
nCLE studies in solid pancreatic masses, which reported rates of
adverse events ranging from 0%–4.5% [20, 21]. nCLE has been
used more widespread in pancreatic cysts, but also for that in-
dication, the rate of adverse events are low, thus the method
can be considered safe [23].
With the use of nCLE, Giovaninni et al. and Kongkam et al.
presented an accuracy of pancreatic ductal adenocarcinoma of
85.0% and 90.9%, respectively. When we assessed the pro-
posed criteria, we were unable to reproduce these excellent re-
sults. For experts the accuracy of dark aggregates > 40µm or di-
lated irregular vessels with fluorescein leakage was limited to
58% (95%CI: 38–71), while it was 63% (95%CI: 44–74) for
CLE novices. Furthermore, the presumed predictors of a benign
diagnosis (dark lobular structures/normal acinar cells fine white
fibrous bands) also failed to reach diagnostic values that in
combination with EUS-FNA would benefit in a clinical setting.
This might reflect a lack of experience and that initial nCLE se-
quences included in the study were collected in the early learn-
ing phase. However, the experts in our study were highly ex-
perienced endomicroscopists with both extra- and intraluminal
experience. Furthermore, the diagnostic values were compar-
able for experts and CLE novices. A second explanation could
be that the mean length of nCLE movies in our study was lim-
ited to 3.5 minutes, compared to 6 (range 2–10) and 8.2
(range 1–32) minutes for Giovaninni and Kongkam, respective-
ly. The criteria analysed in our study were clearly described, but
further precision of the criteria, might increase the diagnostic
value. Due to the high specificity for IPMN’s and serous cystic
lesions of the pancreas, nCLE has gained widespread use for
this indication [16, 24, 25]. However, with the technology avail-
able and the current criteria, we find nCLE unable to distinguish
benign from malignant solid lesions in the pancreas.
A limitation in our study was the number of patients includ-
ed and the fact that the patients were not consecutively enrol-
led. The limited number of patients calls for cautious interpre-
Video 1 The video is from a benign pancreatic lesion in a pa-
tient with chronic pancreatitis. Normal acinar cells are displayed
in the top of the video, while a vessel is present in the lower part.
Video 2 The nCLE video shows pseudoglandular structures in
a patient with pancreatic ductal adenocarcinoma. The structures
are displayed both horizontally and tangentially.
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tation of the results, while the latter might have increased the
risk of selection bias. The study period was prolonged mainly
due to limited research resources, as the nCLE fibers are not re-
imbursed. Furthermore, larger prospective trials may have the
power to estimate if location and size of the lesion affect the
imaging quality and subsequently the diagnostic value.
The reproducibility of luminal CLE parameters has been ex-
tensively studied for Barrett’s esophagus, IBD and colorectal
polyps. In general, the results have been suitable for a clinical
setting with acceptable inter- and intra-observer values [26–
31]. Recently, the nCLE criteria for pancreatic cystic neoplasms
have been evaluated. Napoleon et al found inter-observer val-
ues ranging from fair for mucinous cystic neoplasms to perfect
for pancreatic pseudocysts. Overall inter-observer agreement
was substantial (κ=0.72) [17]. In contrast, Karia et al found re-
latively low inter-observer agreement ranging from poor to fair
[24]. In solid masses, the reproducility of the nCLE parameters
has been less extensively investigated. Both in the inter- and
the intra-observer study, we found values ranging from slight
to moderate. Intensified training might increase the inter- and
intra-observer variability; nonetheless, with the current criteria
the reproducibility of the nCLE parameters is unacceptable for
implementation in a clinical or even an investigational setting.
Furthermore, it is important to keep in mind that EUS-FNA
alone has a sensitivity around 90% for malignancy thus it is
questionable whether the adjunct of nCLE can improve the di-
agnostic value further.
Conclusion
EUS-guided nCLE procedures in focal pancreatic masses are fea-
sible and safe. Nevertheless, the diagnostic value as an adjunct
to EUS-FNA seems limited and further development of the
technology and precision of the diagnostic criteria are needed
before further studies can be undertaken.
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